| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Novartis AG (SW: NOVN)
NOVN Technical Analysis
4
| As on 25th Apr 2025 NOVN SHARE Price closed @ 92.54 and we RECOMMEND Buy for LONG-TERM with Stoploss of 91.83 & Strong Buy for SHORT-TERM with Stoploss of 86.95 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NOVNSHARE Price
| Open | 92.31 | Change | Price | % |
| High | 93.15 | 1 Day | 0.54 | 0.59 |
| Low | 91.66 | 1 Week | 3.80 | 4.28 |
| Close | 92.54 | 1 Month | -3.77 | -3.91 |
| Volume | 3129662 | 1 Year | 8.30 | 9.85 |
| 52 Week High 102.70 | 52 Week Low 82.96 | ||||
SW Switzerland Most Active Stocks
| CSGN | 0.82 | 0.00% |
| CSGN | 0.82 | 0.00% |
| UBSG | 24.79 | 1.31% |
| UBSG | 24.79 | 1.31% |
| NESN | 85.74 | -1.94% |
| NESN | 85.74 | -1.94% |
| NOVN | 92.54 | 0.59% |
| NOVN | 92.54 | 0.59% |
| ABBN | 43.25 | 2.22% |
| ABBN | 43.25 | 2.22% |
SW Switzerland Top Gainers Stocks
SW Switzerland Top Losers Stocks
| NOVN Daily Charts |
NOVN Intraday Charts |
Whats New @ Bazaartrend |
NOVN Free Analysis |
|
|
NOVN Important Levels Intraday
| RESISTANCE | 95.41 |
| RESISTANCE | 94.49 |
| RESISTANCE | 93.92 |
| RESISTANCE | 93.35 |
| SUPPORT | 91.73 |
| SUPPORT | 91.16 |
| SUPPORT | 90.59 |
| SUPPORT | 89.67 |
NOVN Forecast April 2025
| 4th UP Forecast | 113.53 |
| 3rd UP Forecast | 106.8 |
| 2nd UP Forecast | 102.64 |
| 1st UP Forecast | 98.48 |
| 1st DOWN Forecast | 86.6 |
| 2nd DOWN Forecast | 82.44 |
| 3rd DOWN Forecast | 78.28 |
| 4th DOWN Forecast | 71.55 |
NOVN Weekly Forecast
| 4th UP Forecast | 96.80 |
| 3rd UP Forecast | 95.43 |
| 2nd UP Forecast | 94.59 |
| 1st UP Forecast | 93.74 |
| 1st DOWN Forecast | 91.34 |
| 2nd DOWN Forecast | 90.49 |
| 3rd DOWN Forecast | 89.65 |
| 4th DOWN Forecast | 88.28 |
NOVN Forecast2025
| 4th UP Forecast | 134.2 |
| 3rd UP Forecast | 120.84 |
| 2nd UP Forecast | 112.58 |
| 1st UP Forecast | 104.32 |
| 1st DOWN Forecast | 80.76 |
| 2nd DOWN Forecast | 72.5 |
| 3rd DOWN Forecast | 64.24 |
| 4th DOWN Forecast | 50.88 |
Novartis AG ( SW Switzerland Symbol : NOVN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NOVN Business Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Address: Lichtstrasse 35, Basel, Switzerland, 4056
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service